Cited by 792Hormonal and reproductive studiesBone health and osteoporosis researchGrowth Hormone and Insulin-like Growth Factors

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.

Katznelson, L, Finkelstein, J S, Schoenfeld, D A, Rosenthal, D I, Anderson, E J, Klibanski, A·1996·The Journal of Clinical Endocrinology & Metabolism

DOI 10.1210/jcem.81.12.8954042

Open this paper in CoChat — free account

Abstract

Acquired hypogonadism is being increasingly recognized in adult men. However, the effects of long term testosterone replacement on bone density and body composition are largely unknown. We investigated 36 adult men with acquired hypogonadism (age, 22-69 yr; median, 58 yr), including 29 men with central hypogonadism and 7 men with primary hypogonadism, and 44 age-matched eugonadal controls. Baseline evaluation included body composition analysis by bioimpedance, determination of site-specific adipose area by dual energy quantitative computed tomography scan (QCT) of the lumbar spine, and measurements of spinal bone mineral density (BMD) using dual energy x-ray absortiometry, spinal trabecular BMD with QCT, and radial BMD with single photon absorptiometry. Percent body fat was significantly greater in the hypogonadal men compared to eugonadal men (mean +/- SEM, 26.4 +/- 1.1% vs. 19.2 +/- 0.8%; P < 0.01). The mean trabecular BMD determined by QCT for the hypogonadal men was 115 +/- 6 mg K2HPO4/cc. Spinal BMD was significantly lower than that in eugonadal controls (1.006 +/- 0.024 vs. 1.109 +/- 0.028 g/cm2; P = 0.02, respectively). Radial BMD was similar in both groups. Testosterone enanthate therapy was initiated in 29 hypogonadal men at a dose of 100 mg/week, and the subjects were evaluated at 6-month intervals for 18 months. During testosterone therapy, the percent body fat decreased 14 +/- 4% (P < 0.001). There was a 13 +/- 4% decrease in subcutaneous fat (P < 0.01) and a 7 +/- 2% increase in lean muscle mass (P = 0.01) during testosterone therapy. Spinal BMD and trabecular BMD increased by 5 +/- 1% (P < 0.001) and 14 +/- 3% (P < 0.001), respectively. Radial BMD did not change. Serum bone-specific alkaline phosphatase and urinary deoxypyridinoline excretion, markers of bone formation and resorption, respectively, decreased significantly over the 18 months (P = 0.003 and P = 0.04, respectively). We conclude that testosterone therapy given to adult men with acquired hypogonadism decreases sc fat and increases lean muscle mass. In addition, testosterone therapy reduces bone remodeling and increases trabecular bone density. The beneficial effects of androgen administration on body composition and bone density may provide additional indications for testosterone therapy in hypogonadal men.

Integrity signals

Registry

Crossref · 10.1210/jcem.81.12.8954042

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hip fractures in the elderly: A world-wide projection
Cooper, C. C., Campion, G., & Melton, L. J. (1992) · Osteoporosis International · doi:10.1007/bf01623184 · Cited by 3,225
Measurement of Bone Mineral in vivo: An Improved Method
CAMERON, J. R., & Sorenson, J. A. (1963) · Science · doi:10.1126/science.142.3589.230 · Cited by 827
Effects of testosterone supplementation in the aging male.
Tenover, J. S. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.4.1400877 · Cited by 702
Risk factors for spinal osteoporosis in men
Seeman, E., Melton, L. J., O’Fallon, W. M., & Riggs, B. L. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90878-1 · Cited by 658
Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis
Urban, R. J., Bodenburg, Y. H., Gilkison, C., Foxworth, J., Coggan, A. R., Wolfe, R. R., & Ferrando, A. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.269.5.e820 · Cited by 608
Osteoporosis: Etiology, diagnosis, and management
(1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)80791-1 · Cited by 605
Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels
Seidell, J. C., Björntorp, P., Sjöström, L., Kvist, H., & Sannerstedt, R. (1990) · Metabolism · doi:10.1016/0026-0495(90)90297-p · Cited by 567
Effects of Testosterone Replacement Therapy in Old Hypogonadal Males: A Preliminary Study
Morley, J. E., Perry, H. M., Kaiser, F. E., Kraenzle, D., Jensen, J., Houston, K., Mattammal, M. B., & Perry, H. M. (1993) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1993.tb02049.x · Cited by 462
Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor.
Bellido, T., Jilka, R. L., Boyce, B. F., Girasole, G., Broxmeyer, H. E., Dalrymple, S. A., Murray, R., & Manolagas, S. C. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117995 · Cited by 429
Castrated Men Exhibit Bone Loss: Effect of Calcitonin Treatment on Biochemical Indices of Bone Remodeling*
Stepan, J. J., Lachman, M., ZVĚŘINA, J., Pacovský, V., & Baylink, D. J. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-523 · Cited by 423

Show all 38 references

Sorted by citations

Items 201–300 of 792

Testosterone Is Significantly Reduced in Endurance Athletes without Impact on Bone Mineral Density
Maïmoun, L., Lumbroso, S., Manetta, J., Paris, F., Leroux, J. L., & Sultan, C. (2003) · Hormone Research in Paediatrics · doi:10.1159/000070627 · Cited by 76
Effects of Age on Testicular Function and Consequences of Testosterone Treatment
Snyder, P. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7602 · Cited by 82
“In one study, 29 hypogonadal men who were treated with 100 mg testosterone enanthate once a week for 18 months experienced an increase in bone mineral density of the lumbar spine by 5% ( 19 ).”
Background
Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit
Sambrook, P. N., Seeman, E., Phillips, S. R., & Ebeling, P. R. (2002) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2002.tb04475.x · Cited by 77
Anabolic Interventions for Aging-Associated Sarcopenia
Bross, R., Javanbakht, M., & Bhasin, S. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6055 · Cited by 75
Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male
Jones, S. D., Dukovac, T., Sangkum, P., Yafi, F. A., & Hellstrom, W. J. G. (2015) · Sexual Medicine Reviews · doi:10.1002/smrj.43 · Cited by 76
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy
Bell, J. M., Shields, M. D., Watters, J., Hamilton, A., Beringer, T. R. O., Elliott, M., Quinlivan, R. C. M., Tirupathi, S., & Blackwood, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010899.pub2 · Cited by 77
Effect of Testosterone Treatment on Bone Microarchitecture and Bone Mineral Density in Men: A 2-Year RCT
Fui, M. N. T., Hoermann, R., Bracken, K., Handelsman, D. J., Inder, W. J., Stuckey, B. G. A., Yeap, B. B., Ghasemzadeh, A., Robledo, K. P., Jesudason, D. R., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab149 · Cited by 80
“Pathological hypogonadism due to pituitary or testicular disease is a risk factor for osteoporosis in men (1) and testosterone replacement increases bone mineral density (BMD) (2).”
Short stature and pubertal delay in Duchenne muscular dystrophy
Wood, C. L., Straub, V. W., Guglieri, M., Bushby, K. M. D., & Cheetham, T. D. (2015) · Archives of Disease in Childhood · doi:10.1136/archdischild-2015-308654 · Cited by 75
Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of β-catenin
Gentile, M. A., Nantermet, P. V., Vogel, R. L., Phillips, R., Holder, D., Hodor, P. G., Cheng, C., Dai, H. A., Freedman, L. P., & Ray, W. J. (2009) · Journal of Molecular Endocrinology · doi:10.1677/jme-09-0048 · Cited by 75
“Treatment with testosterone improves muscle mass and strength, bone density, and reduces visceral fat in a variety of subjects (Bardin 1996, Katznelson et al. 1996, Bhasin et al. 1997, 2000, Swerdloff & Wang 2003).”
Background
Development of models to predict anabolic response to testosterone administration in healthy young men
Woodhouse, L. J., Reisz-Porszasz, S., Javanbakht, M., Storer, T. W., Lee, M., Zerounian, H., & Bhasin, S. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00536.2002 · Cited by 73
“4%; and IGF-I, 80 ng/ml, 4 and 6%, respectively (3, 6, 18, 29).”
Background
Interrelationships among Lipoprotein Levels, Sex Hormones, Anthropometric Parameters, and Age in Hypogonadal Men Treated for 1 Year with a Permeation-Enhanced Testosterone Transdermal System1
Dobs, A. S., Bachorik, P. S., Arver, S., Meikle, A. W., Sanders, S. W., Caramelli, K. E., & Mazer, N. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7285 · Cited by 73
“This suggests that the observed weight gain may have resulted from an increase in lean mass rather than fat mass, as seen in other testosterone replacement studies in hypogonadal men in which body composition was measured (57, 58).”
Result
Cystic fibrosis bone disease treatment: Current knowledge and future directions
Putman, M. S., Anabtawi, A., Le, T. N. H., Tangpricha, V., & Sermet‐Gaudelus, I. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.08.017 · Cited by 72
Comparison of dried plum supplementation and intermittent PTH in restoring bone in osteopenic orchidectomized rats
Bu, S. Y., Lucas, E. A., Franklin, M. A., Marlow, D. D., Brackett, D. J., Boldrin, E., Devareddy, L., Arjmandi, B. H., & Smith, B. J. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0335-y · Cited by 73
“There are concerns regarding the abrupt withdrawal of gonadal hormones in the ORX animal model, which does not typically occur in men with the exception of severe hypogonadism due to castration [34].”
Background
Drug Insight: testosterone preparations
Srinivas-Shankar, U., & Wu, F. C. W. (2006) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0650 · Cited by 72
“decreases subcutaneous fat, increases lean muscle mass, reduces bone remodeling, and increases trabecular bone density”
Background
Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study
Rolf, C., von Eckardstein, S., Koken, U. H., & Nieschlag, E. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460505 · Cited by 72
Testosterone metabolites differentially regulate obesogenesis and fat distribution
Sebo, Z. L., & Rodeheffer, M. S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101141 · Cited by 71
“By contrast, treating hypogonadal men with testosterone has been shown to preferentially reduce either visceral [27,28] or subcutaneous fat stores [29,30], and a role for DHT in fat distribution has not been reported.”
Background
Clinical Practice Manual for Late‐onset Hypogonadism Syndrome
Namiki, M., Akaza, H., Shimazui, T., Ito, N., Iwamoto, T., Baba, K., Kumano, H., Koh, E., Tsujimura, A., Matsumiya, K., et al. (2008) · International Journal of Urology · doi:10.1111/j.1442-2042.2008.02010.x · Cited by 71
Androgen Deficiency in Women1
Miller, K. K. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7610 · Cited by 70
“Androgen deficiency in men is associated with an increase in percent body fat (5), and androgen administration results in a diminution in total and visceral fat, an increase in lean mass, and a reduction in total cholesterol and low density lipoprotein (LDL) in men (5, 58).”
Background
Evidence for Tissue Selectivity of the Synthetic Androgen 7α-Methyl-19-Nortestosterone in Hypogonadal Men
Anderson, R. A., Wallace, A. M., Sattar, N. A., Kumar, N., & Sundaram, K. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021960 · Cited by 69
Solubilizing steroidal drugs by β-cyclodextrin derivatives
Schwarz, D. H., Engelke, A., & Wenz, G. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.046 · Cited by 69
Optimizing Skeletal Muscle Anabolic Response to Resistance Training in Aging
Endo, Y., Nourmahnad, A., & Sinha, I. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00874 · Cited by 77
“Androgenic depravation may be a factor contributing to sarcopenia in old males (Katznelson et al., 1996; Kenny et al., 2001; Ly et al., 2001).”
Background
9 Osteoporosis in men
Seeman, E. (1997) · Baillière s Clinical Rheumatology · doi:10.1016/s0950-3579(97)80023-4 · Cited by 69
“[93] reportedthat 36 hypogonadalmen (29 with hypogonadotropichypogonadism),aged 22–69 years,had lower lumbar BMD andsimilar radial BMD by single photon absorptiometryrelative to 44 agematchedcontrols.”
Augmentation of Bone Mineral Density in Hirsute Women
Dagogo-Jack, S., Al-Ali, N. S., & Qurtom, M. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.9.4246 · Cited by 75
“The reasons for the latter findings are unclear, but may well be related to differential effects of hyperandrogenism on musculoskeletal and soft tissue body composition (25).”
Background
Experience With Testosterone Replacement in the Elderly
Tenover, J. L. (2000) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(19)30648-2 · Cited by 69
Androgen effects on body composition
Bhasin, S., Woodhouse, L. J., & Storer, T. W. (2003) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(03)00058-3 · Cited by 68
“lower fat-free mass and higher fat mass when compared to age-matched eugonadal men [8,10].”
Background
Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men
Aminorroaya, A., Kelleher, S., Conway, A. J., Ly, L. P., & Handelsman, D. J. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01920 · Cited by 68
Body composition, metabolic syndrome and testosterone in ageing men
Allan, C. A., Strauss, B. J. G., & McLachlan, R. I. (2007) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901552 · Cited by 67
Reliability of Maximal Voluntary Muscle Strength and Power Testing in Older Men
Schroeder, E. T., Wang, Y., Castaneda‐Sceppa, C., Cloutier, G. J., Vallejo, A. F., Kawakubo, M., Jensky, N. E., Coomber, S., Azen, S. P., & Sattler, F. R. (2007) · The Journals of Gerontology Series A · doi:10.1093/gerona/62.5.543 · Cited by 67
Effects of an oral androgen on muscle and metabolism in older, community-dwelling men
Schroeder, E. T., Singh, A. B., Bhasin, S., Storer, T. W., Azen, C. G., Davidson, T., Martinez, C., Sinha‐Hikim, I., Jaque, S. V., Terk, M. R., et al. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00363.2002 · Cited by 67
Mechanisms of bone loss after cardiac transplantation
Guo, C.-Y., Johnson, A., Locke, T. J., & Eastell, R. (1998) · Bone · doi:10.1016/s8756-3282(97)00269-x · Cited by 67
Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized‐controlled trial
Dias, J. P., Melvin, D., Simonsick, E. M., Carlson, O., Shardell, M. D., Ferrucci, L., Chia, C. W., Basaria, S., & Egan, J. M. (2016) · Andrology · doi:10.1111/andr.12126 · Cited by 65
“Testosterone (T) levels in men decline with age (Harman et al., 2001) and this decline is associated with loss of lean body mass (LBM), muscle strength, and bone mineral density (BMD) observed in most individuals as they age (Jackson et al., 1992; Katznelson et al., 1996; Behre et al., 1997).”
Background
Testosterone supplementation and bone parameters: a systematic review and meta-analysis study
Corona, G., Vena, W., Pizzocaro, A., Giagulli, V. A., Francomano, D., Rastrelli, G., Mazziotti, G., Aversa, A., Isidori, A. M., Pivonello, R., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01702-5 · Cited by 71
Does oestrogen allow women to store fat more efficiently? A biological advantage for fertility and gestation
O’Sullivan, A. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2008.00539.x · Cited by 67
“In some studies, testosterone administration to hypogonadal or elderly men does not alter fat mass (33–37), whereas in others fat mass decreases (38,39).”
Background
A crosstalk between bone and gonads
Oury, F. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06360.x · Cited by 66
Effects of Gonadal Steroid Suppression on Skeletal Sensitivity to Parathyroid Hormone in Men
Leder, B. Z., Smith, M. R., Fallon, M. A., Lee, M. T., & Finkelstein, J. S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7177 · Cited by 70
Self-citation
Anemia, testosterone, and pituitary adenoma in men
Ellegala, D. B., Alden, T. D., Couture, D. E., Vance, M. L., Maartens, N. F., & Laws, E. R. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.98.5.0974 · Cited by 63
Male Osteoporosis
Kamel, H. K. (2005) · Drugs & Aging · doi:10.2165/00002512-200522090-00003 · Cited by 64
Effects of modest testosterone supplementation and exercise for 12 weeks on body composition and quality of life in elderly men
Katznelson, L. J., Robinson, M. W., Coyle, C. L., Lee, H., & Farrell, C. E. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02291 · Cited by 62
Self-citation
Role of Medicinal Plants and Natural Products on Osteoporotic Fracture Healing
Jalil, M. A. A., Shuid, A. N., & Muhammad, N. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/714512 · Cited by 62
Regulation of body composition by androgens
Bhasin, S. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03345230 · Cited by 63
For and against: The male menopause---does it exist? For Against
Gould, D. C. (2000) · BMJ · doi:10.1136/bmj.320.7238.858 · Cited by 60
Cortical Bone Loss in Androgen-Deficient Aged Male Rats Is Mainly Caused by Increased Endocortical Bone Remodeling
Reim, N. S., Breig, B., Stähr, K., Eberle, J., Hoeflich, A., Wolf, E., & Erben, R. G. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080202 · Cited by 59
Androgen deprivation therapy for prostate cancer: Effects on hand function
Soyupek, F., Soyupek, S., Perk, H., & Özorak, A. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2006.12.014 · Cited by 60
Andropause:
Morley, J. E., & Perry, H. M. (2003) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00105-2 · Cited by 60
“Testosterone produces a mild increase or no effect on prostate-specific antigen (see Table 8) [59,60,63–66,70,123].”
BackgroundInfluential
Male hypogonadism: pathogenesis, diagnosis, and management
de Silva, N. L., Papanikolaou, N., Grossmann, M., Antonio, L., Quinton, R., Anawalt, B. D., & Jayasena, C. N. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00199-2 · Cited by 68
Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis
Yurçi, A., Yücesoy, M., Ünlühızarcı, K., Torun, E., Gürsoy, Ş., Başkol, M., Güven, K., & Özbakır, Ö. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.09.005 · Cited by 59
Male Hypogonadism
Darby, E. L., & Anawalt, B. D. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504050-00003 · Cited by 60
Effects of anabolic-androgenic steroid use or gonadal testosterone suppression on serum leptin concentration in men
Hislop, M., Ratanjee, B., Soule, S. G., & Marais, A. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410040 · Cited by 59
“Sex steroid supplementation has a more pronounced effect on body fat mass in these individuals, possibly because they tend to have a body fat percentage that is greater than that in eugonadal males ( 34 ).”
Age-Associated Sarcopenia--Issues in the Use of Testosterone as an Anabolic Agent in Older Men
D, S. B. M., & Tenover, J. L. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.6.4061 · Cited by 58
Cardiovascular Effects of Androgens
Weidemann, W. M., & Hanke, H. (2002) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2002.tb00086.x · Cited by 58
Endocrine complications of anorexia nervosa
Haines, M. S. (2023) · Journal of Eating Disorders · doi:10.1186/s40337-023-00744-9 · Cited by 66
“Although testosterone has been shown to increase BMD in older men with osteoporosis and younger men with hypogonadism [118, 119], a randomized controlled trial of testosterone replacement in adolescent boys and men with AN has not been performed.”
Background
Sexual dimorphism in skeletal muscle protein turnover
Smith, G. I., & Mittendorfer, B. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00625.2015 · Cited by 65
“Hypoandrogenemia is associated with a reduced lean body mass (58), and treatment with testosterone increases the muscle protein synthesis rate (14, 45, 103, 113).”
Background
The effects of oestrogen exposure on bone mass in male to female transsexuals
Reutrakul, S., Ongphiphadhanakul, B., Piaseu, N., Krittiyawong, S., Chanprasertyothin, S., Bunnag, P., & Rajatanavin, R. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00614.x · Cited by 59
“In men, various forms of hypogonadism are associated with lower BMD that improves significantly after restoration of a eugonodal state, usually by testosterone administration (Finkenstein et al., 1989; Greenspan et al., 1989; Katznelson et al., 1996).”
Background
Serum Dihydrotestosterone and Testosterone Concentrations in Human Immunodeficiency Virus‐Infected Men With and Without Weight Loss
Arver, S., Sinha‐Hikim, I., Beall, G. N., GUERRERO, M., Shen, R., & Bhasin, S. (1999) · Journal of Andrology · doi:10.1002/j.1939-4640.1999.tb02562.x · Cited by 55
Sex Steroids, Precursors, and Metabolite Deficiencies in Men With Isolated Hypogonadotropic Hypogonadism and Panhypopituitarism: A GCMS-Based Comparative Study
Giton, F., Trabado, S., Maione, L., Sarfati, J., Bouc, Y. L., Brailly‐Tabard, S., Fiet, J., & Young, J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2658 · Cited by 57
“Therefore, unless they are treated with an aromatizable androgen or gonadotropins with LH activity (5), these men may be more at risk of osteoporosis (16, 17), sexual dysfunction (18), increases in body fat (18), and metabolic syndrome than men with IHH.”
Background
The aging population – Is there a role for endocrine interventions?
Nass, R. M., Johannsson, G., Christiansen, J. S., Kopchick, J. J., & Thorner, M. O. (2008) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2008.09.002 · Cited by 56
“Studies of young, hypogonadal men have reported a decrease in fat mass with testosterone replacement [116], whereas others did not find a change [117].”
Background
Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men
Basurto, L., Zárate, A., Gómez, R. N. M. M., Vargas, C. D. V., Saucedo, R., & Galván, R. E. (2008) · The Aging Male · doi:10.1080/13685530802273715 · Cited by 56
Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy
Duarte, R. V., Raphael, J. H., Southall, J. L., Labib, M. H., Whallett, A. J., & Ashford, R. L. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002856 · Cited by 55
Double‐blind placebo‐controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism
Merza, Z., Blumsohn, A., Mah, P., Meads, D. M., McKenna, S. P., Wylie, K. R., Eastell, R., Wu, F. C. W., & Ross, R. J. M. (2005) · International Journal of Andrology · doi:10.1111/j.1365-2605.2005.00612.x · Cited by 54
Opioid-induced hypogonadism: why and how to treat it.
de Maddalena, C., Bellini, M., Berra, M., Meriggiola, M. C., & Aloisi, A. M. (2012) · PubMed · Cited by 55
Unresolved Issues in Osteoporosis in Men
Seeman, E. (2001) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1010054924085 · Cited by 54
Transdermal Testosterone Application: Pharmacokinetics and Effects on Pubertal Status, Short-Term Growth, and Bone Turnover
Mayo, A., MacIntyre, H. E., Wallace, E. M., & Ahmed, S. F. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031086 · Cited by 55
Male acquired hypogonadotropic hypogonadism: Diagnosis and treatment
Salenave, S., Trabado, S., Maione, L., Brailly‐Tabard, S., & Young, J. (2012) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.03.040 · Cited by 51
Effects of testosterone replacement and its pharmacogenetics on physical performance and metabolism
Zitzmann, M. (2008) · Asian Journal of Andrology · doi:10.1111/j.1745-7262.2008.00405.x · Cited by 53
Opioid-Induced Hypogonadism: Why and How to Treat It
Aloisi, A. M. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/es111 · Cited by 66
Testosterone administration attenuates regional brain hypometabolism in women with anorexia nervosa
Miller, K. K., Deckersbach, T., Rauch, S. L., Fischman, A. J., Grieco, K. A., Herzog, D. B., & Klibanski, A. (2004) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2004.09.003 · Cited by 54
Self-citation
Transgender Primary Medical Care
Feldman, J., & Goldberg, J. M. (2006) · International Journal of Transgenderism · doi:10.1300/j485v09n03_02 · Cited by 54
Δ-4-Androstene-3,17-Dione Binds Androgen Receptor, Promotes Myogenesisin Vitro, and Increases Serum Testosterone Levels, Fat-Free Mass, and Muscle Strength in Hypogonadal Men
Jasuja, R., Ramaraj, P., Mac, R. P., Singh, A. B., Storer, T. W., Artaza, J., Miller, A., Singh, R., Taylor, W. E., Lee, M. L., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1577 · Cited by 53
Androgen Supplementation in Older Women: Too Much Hype, Not Enough Data
Padero, M., Bhasin, S., & Friedman, T. C. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50273.x · Cited by 53
Sex steroids and the kidney: role in renal calcium and phosphate handling
Khalil, R., Kim, N. R., Jardi, F., Vanderschueren, D., Claessens, F., & Decallonne, B. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.11.011 · Cited by 53
“Androgen replacement therapy in young adult and older hypogonadal men has been shown to both decrease serum calcium levels (Katznelson et al., 1996), while other studies showed no significant changes (Morley et al., 1993; Tenover, 1992).”
Result
Sex hormones, body composition and aging
Vermeulen, A., Goemaere, S., & Kaufman, J. (1999) · The Aging Male · doi:10.3109/13685539909003178 · Cited by 55
Endocrinology & Dialysis. Testosterone Metabolism and Replacement Therapy in Patients with End‐Stage Renal Disease
Holley, J. L., & Johansen, K. L. (2004) · Seminars in Dialysis · doi:10.1111/j.0894-0959.2004.17307.x · Cited by 54
Relationship of Androgens to Muscle Size and Bone Mineral Density in Women With Polycystic Ovary Syndrome
Douchi, T., Oki, T., Yamasaki, H., Kuwahata, R., Nakae, M., & Nagata, Y. (2001) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(01)01450-8 · Cited by 53
Male Osteoporosis: Deadly, but Ignored
Gruntmanis, U. (2007) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200702000-00004 · Cited by 52
Assessment and Recommendations on Factors Contributing to Preanalytical Variability of Urinary Pyridinoline and Deoxypyridinoline
Vesper, H. W., Demers, L. M., Eastell, R., et al. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.2.220 · Cited by 52
The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.
Matsumoto, A. M., Tenover, J. L., McClung, M. R., Mobley, D. F., Geller, J., Sullivan, M. J., Grayhack, J. T., Wessells, H., Kadmon, D., Flanagan, M. J., et al. (2002) · PubMed · Cited by 52
Reduced Bone Density in Androgen-Deficient Women with Acquired Immune Deficiency Syndrome Wasting
Huang, J. S., Wilkie, S. J., Sullivan, M. P., & Grinspoon, S. K. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3533 · Cited by 52
Background for studies on the treatment of male osteoporosis: state of the art
Kaufman, J., Johnell, O., Abadie, E., Adami, S., Audran, M., Avouac, B., Sedrine, W. B., Calvo, G., Devogelaer, J. P., Fuchs, V., et al. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.10.765 · Cited by 51
“Giving testosterone to adult men with acquired hypogonadism has been reported to reduce bone turnover and increase bone density,”
Background
Biochemical Markers of Bone Turnover in Osteoporosis
Szulc, P., Bauer, D. C., & Eastell, R. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch35 · Cited by 51
Bone mineral density and estimated hip strength in men with anorexia nervosa, atypical anorexia nervosa and avoidant/restrictive food intake disorder
Haines, M. S., Drabkin, A. D., Rothman, M. S., Meenaghan, E. M., Lashen, G. T., Mascolo, M., Watters, A., Holmes, T. M., Santoso, K., Yu, E. W.-Y., et al. (2019) · Clinical Endocrinology · doi:10.1111/cen.13960 · Cited by 52
Self-citation
The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition
Howell, S. J., Radford, J. A., Adams, J. E., & Shalet, S. M. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00997.x · Cited by 49
“An increase in total body fat, truncal fat, and alterations in the distribution of fat have previously been described in overtly hypogonadal men (Katznelson et al., 1996, 1998).”
Background
Heritability of blood concentrations of sex‐steroids in relation to body composition in young adult male siblings
Bogaert, V., Taes, Y., Könings, P., Steen, K. V., Bacquer, D. D., Goemaere, S., Zmierczak, H., Crabbe, P., & Kaufman, J. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03173.x · Cited by 50
The pituitary-Leydig cell axis before and after orchiectomy in patients with stage I testicular cancer
Bandak, M., Aksglæde, L., Juul, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.026 · Cited by 49
Androgen deficiency in the aging male: benefits and risks of androgen supplementation
Gooren, L. J. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00206-1 · Cited by 49
Neridronate Prevents Bone Loss in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
Morabito, N., Gaudio, A., Lasco, A., Catalano, A., Atteritano, M., Trifiletti, A., Anastasi, G., Melloni, D., & Frisina, N. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040813 · Cited by 48
Male osteoporosis: A review
Herrera, A. (2012) · World Journal of Orthopedics · doi:10.5312/wjo.v3.i12.223 · Cited by 48
Characterization of the male ApcMin/+ mouse as a hypogonadism model related to cancer cachexia
White, J. P., Puppa, M. J., Narsale, A. A., & Carson, J. (2013) · Biology Open · doi:10.1242/bio.20136544 · Cited by 48
“, 1996) or without (Katznelson et al., 1996; Mauras et al., 1998) an underlying disease.”
Background
Aging and Muscle Loss
Bross, R., Storer, T., & Bhasin, S. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(98)00143-x · Cited by 48
Testosterone in older men after the Institute of Medicine Report: where do we go from here?
Harman, S. M. (2005) · Climacteric · doi:10.1080/13697130500118001 · Cited by 46
The Long-Term Effect Of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial
Matsumoto, A. M., Tenover, J. L., McClung, M. R., Mobley, D. F., Geller, J., Sullivan, M. J., Grayhack, J. T., Wessells, H., Kadmon, D., Flanagan, M. J., et al. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)65095-1 · Cited by 47
Gender-Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen
Vlot, M. C., Wiepjes, C. M., de Jongh, R. T., T'Sjoen, G. G., Heijboer, A. C., & den Heijer, M. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3762 · Cited by 48
Testosterone Deficiency as One of the Major Endocrine Disorders in Chronic Kidney Disease
Romejko, K., Rymarz, A., Sadownik, H., & Niemczyk, S. (2022) · Nutrients · doi:10.3390/nu14163438 · Cited by 52
Osteoporosis and Other Adverse Body Composition Changes during Androgen Deprivation Therapy for Prostate Cancer
Smith, M. R. (2002) · Cancer and Metastasis Reviews · doi:10.1023/a:1020840311573 · Cited by 46
“Some but not all studies have reported that testosterone replacement therapy decreases fat mass in hypogonadal men [52,56,57].”
Background
Osteoporosis in Male Hypogonadism: Responses to Androgen Substitution Differ among Men with Primary and Secondary Hypogonadism
Schubert, M., Bullmann, C., Minnemann, T., Reiners, C., Krone, W., & Jockenhövel, F. (2003) · Hormone Research in Paediatrics · doi:10.1159/000070823 · Cited by 45
“Despite the widespread assumption that testosterone substitution increases the bone mineral density (BMD) in male hypogonadism, evidence is based on very small patient numbers [”
Background
The aging male: testosterone deficiency and testosterone replacement. An up-date
Alexandersen, P., & Christiansen, C. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00242-9 · Cited by 45
Hormone Replacement Therapy and Fractures in Older Adults
Kamel, H. K., Perry, H. M., & Morley, J. E. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.49040.x · Cited by 44
Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men
Leder, B. Z., & Finkelstein, J. S. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1890-8 · Cited by 44
“Androgen replacement clearly increases BMD in profoundly hypogonadal men [39–42] and older men with mild hypogonadism (such as those enrolled in this study) [11].”
BackgroundSelf-citation
Serum Androgen Levels and Muscle Mass in Women With Polycystic Ovary Syndrome
Douchi, T., YAMAMOTO, S., OKI, T., MARUTA, K., KUWAHATA, R., & NAGATA, Y. (1999) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(99)00311-7 · Cited by 44
Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment
Rosa, M. D., Paesano, L., Nuzzo, V., Zarrilli, S., Puente, A. D., Oriente, P., & Lupoli, G. (2001) · Journal of Endocrinological Investigation · doi:10.1007/bf03343854 · Cited by 44
The relation between bone density, free androgen index, and estradiol in men 60 to 70 years old
Scopacasa, F., Horowitz, M., Wishart, J. M., Morris, H. A., Chatterton, B. E., & Need, A. G. (2000) · Bone · doi:10.1016/s8756-3282(00)00299-4 · Cited by 43

Authors: Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A.
Affiliations: Massachusetts General Hospital (US)
ORCID: Katznelson, L
Finkelstein, J S
Schoenfeld, D A
Rosenthal, D I
Anderson, E J
Venue: The Journal of Clinical Endocrinology & Metabolism
Publisher: The Endocrine Society
Published: 1996-12
Volume: 81
Issue: 12
Pages: 4358-4365
ISSN: 0021-972X (ISSN-L)
1945-7197
DOI: 10.1210/jcem.81.12.8954042
OpenAlex: W1974568933
Semantic Scholar: 829db808d1847d263af6c33d3397743284ea9f83
Cited by: 791
References: 38
Citations by year: 2026: 2 · 2025: 9 · 2024: 12 · 2023: 13 · 2022: 16 · 2021: 15 · 2020: 15 · 2019: 14 · 2018: 17 · 2017: 18 · 2016: 22 · 2015: 24 · 2014: 17 · 2013: 29 · 2012: 35
FWCI: 19.42
Type: journal article
Language: en
Open access: closed
Locations: The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5f32dk008738-02)
National Institute of Diabetes and Digestive and Kidney Diseases (DK-08738)
National Center for Research Resources (RR 01066, M01RR001066)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords: testosterone replacement therapy, testosterone enanthate, bone mineral density, trabecular bone density, lean body mass, body composition, fat mass, central hypogonadism, hypergonadotropic hypogonadism, bone-specific alkaline phosphatase, urinary deoxypyridinoline, bone turnover markers, men's health, osteoporosis prevention
MeSH terms: Adult, Aged, Body Composition, Bone Development, Humans, Hypogonadism, Cholesterol, HDL, Longitudinal Studies, Male, Middle Aged, Parathyroid Hormone, Growth Hormone, Testosterone, Bone Density

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks